Avisi Technologies Raises $10.7 Million Series A to Advance Pivotal Glaucoma Device Trial

New updates have been reported about Avisi Technologies.

Avisi Technologies, Inc., a clinical-stage ophthalmic device company, has secured $10.7 million in Series A funding to advance its VisiPlate® glaucoma shunt through a pivotal U.S. trial and deepen its pipeline of glaucoma treatments. The round was led by MedVenture Partners with participation from new institutional and angel investors, while existing backers, including several life sciences and venture funds, increased their commitments, signaling confidence in Avisi’s technology and regulatory trajectory.

Proceeds will primarily fund the SAPPHIRE pivotal trial, which received FDA IDE clearance in 2025 and is now enrolling at multiple U.S. sites to evaluate the safety and efficacy of VisiPlate®, an ultrathin metamaterial shunt designed to reduce intraocular pressure by sustaining aqueous outflow. As part of the financing, MedVenture Partners’ Justin Fukuyama joins Avisi’s board, bolstering governance as the company moves toward potential commercialization, while management continues to build a broader platform that includes a sustained drug-delivery system and a device aimed at mild to moderate glaucoma at the time of cataract surgery.

VisiPlate® is engineered with multiple redundant microchannels and a patented, hair-thin metamaterial intended to minimize scarring, occlusion, and re-interventions that undermine many current glaucoma surgeries. Positive long-term follow-up from the earlier VITA study, recently presented at a major glaucoma meeting, underpins investor interest and supports the company’s view that VisiPlate® could address a critical gap in care for a disease that affects more than 133 million people globally and remains a leading cause of irreversible blindness.

Executives and investors describe this capital raise as a pivotal inflection point, positioning Avisi to generate the clinical evidence needed for potential regulatory submissions, validate its platform technology, and compete in a growing surgical devices market that demands durable, low-maintenance solutions. If SAPPHIRE results are favorable, the company could gain a strategic foothold in advanced glaucoma interventions, open pathways for partnerships with larger ophthalmic players, and leverage its metamaterials expertise across additional ocular indications, although VisiPlate® remains investigational and is not yet approved for sale.